Skip to content
Intended for US healthcare professionals.

Continuous glucose monitoring in type 2 diabetes: what the 2025-26 evidence supports

Across randomized trials in type 2 diabetes, continuous glucose monitoring lowers HbA1c by roughly 0.25 to 0.4 percentage points in pooled analyses, and the evidence is limited in people not on glucose-lowering therapy.

4 min read · 7 references · References retrieved 18 October 2026
Educational content for healthcare professionals. Not medical advice. AI-generated and not authored or reviewed by a licensed physician. Verify against current guidelines and product labeling before any clinical decision.

The American Diabetes Association (ADA) 2026 Standards of Care extend continuous glucose monitoring (CGM) beyond insulin-treated type 2 diabetes [1][2]. A 2026 JAMA Internal Medicine review put the mean HbA1c drop from CGM in type 2 diabetes at about 0.3 percentage points versus finger-stick checks or usual care [3]; the pooled estimates below range from 0.25 to 0.40 [4][5][6].

What changed in the 2026 ADA Standards?

In the ADA Standards of Care in Diabetes-2026, recommendation 7.15 covers CGM from diabetes onset onward in three groups: people on insulin, people on noninsulin drugs that can cause hypoglycemia, and people on any treatment where CGM helps management [1]. The 2026 ADA technology chapter grades the insulin-therapy component of that recommendation A and both noninsulin components C [1].

The 2026 ADA Summary of Revisions drops intermittently scanned CGM as a separate category and keeps three device types: real-time, over-the-counter and professional [2]. The 2026 ADA technology chapter notes that over-the-counter CGM lacks alarms and alerts [1]. The 2026 ADA chapter also states that people using CGM must have access to blood glucose monitoring at all times [1].

How much does CGM lower HbA1c in type 2 diabetes?

  • Noninsulin-treated: in a 2025 meta-analysis of 8 randomized trials (n=541), CGM lowered HbA1c by 0.37 percentage points (95% CI 0.24 to 0.49) versus blood glucose monitoring or usual care [4].
  • Time in range, noninsulin-treated: the same 2025 meta-analysis reported 8.84 percentage points more time in range (95% CI 4.62 to 13.06), with no statistical heterogeneity (I²=0%) [4].
  • Type 2 subgroup, real-time CGM: in a 2025 meta-analysis of 64 randomized trials across type 1, type 2 and pregnancy, real-time CGM in type 2 diabetes lowered HbA1c by 0.40 percentage points (95% CI 0.24 to 0.55) versus self-monitoring [5].
  • Insulin-treated: in a 2026 meta-analysis of 13 randomized trials (n=1,550), CGM lowered HbA1c by 2.78 mmol/mol (95% CI 0.88 to 4.68), about 0.25 percentage points by standard unit conversion, versus self-monitoring [6].

A 2026 randomized trial assigned 303 adults on basal insulin plus a sodium-glucose cotransporter-2 inhibitor or an incretin-based agent (HbA1c 7.5% to 11.0% at entry, mean 8.8%) to real-time CGM or self-monitoring [7]. In the 2026 basal-insulin trial, real-time CGM lowered HbA1c by an adjusted 0.6 percentage points at 16 weeks (95% CI 0.3 to 0.8) and 0.5 percentage points at 32 weeks (95% CI 0.2 to 0.7) versus self-monitoring [7].

Does CGM change hypoglycemia?

In the 2026 insulin-treated meta-analysis, CGM reduced time below range by 1.30 percentage points (95% CI 0.65 to 1.94) versus self-monitoring [6]. Severe hypoglycemia was rare in the 2026 basal-insulin trial: two instances, both in the self-monitoring group [7].

Where is the evidence uncertain?

In the 2026 insulin-treated meta-analysis, heterogeneity for HbA1c was high, with I² near 90% [6]. The same 2026 meta-analysis found a 4.04 percentage-point gain in time in range (95% CI −0.09 to 8.17) that was not significant [6]. The 2026 basal-insulin trial was open-label and industry-funded [7]. The 2026 JAMA Internal Medicine review found only limited, indirect evidence for CGM in type 2 diabetes without glucose-lowering therapy [3]. The review concludes that CGM should be deployed in response to a specific patient problem rather than as a default intervention [3].

Checks at the point of care

  • Current therapy: insulin, a noninsulin agent that can cause hypoglycemia, or neither; the 2026 ADA evidence grade differs by group, A versus C [1].
  • Device category: whether the device is a real-time CGM, most of which have adjustable alarms and alerts, or an over-the-counter CGM, which lacks them [1].
  • Baseline HbA1c: whether it falls in the 7.5% to 11.0% range enrolled in the 2026 basal-insulin trial [7].
  • Defined clinical problem: whether a specific patient problem is the reason for CGM [3].
  • Meter access: whether the patient has blood glucose monitoring available at all times, which the 2026 ADA technology chapter states people using CGM must have [1].

References

  1. American Diabetes Association Professional Practice Committee for Diabetes. 7. Diabetes Technology: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S150-S165. doi:10.2337/dc26-S007. https://pubmed.ncbi.nlm.nih.gov/41358889/ — accessed 18 October 2026.
  2. American Diabetes Association Professional Practice Committee for Diabetes. Summary of Revisions: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S6-S12. doi:10.2337/dc26-SREV. https://pubmed.ncbi.nlm.nih.gov/41358896/ — accessed 18 October 2026.
  3. Dower JA, Johansson M, Camp AW, Montori VM, Lipska KJ. Continuous glucose monitoring in type 2 diabetes and beyond: a review. JAMA Intern Med. 2026;186(9):1166-1173. doi:10.1001/jamainternmed.2026.2772. https://pubmed.ncbi.nlm.nih.gov/42545686/ — accessed 18 October 2026.
  4. Aronson R, Abitbol A, Bajaj HS, et al. Continuous glucose monitoring in noninsulin-treated type 2 diabetes: a critical review of reported trials with an updated systematic review and meta-analysis of randomised controlled trials. Diabetes Obes Metab. 2025;27(11):6220-6242. doi:10.1111/dom.70008. https://pubmed.ncbi.nlm.nih.gov/40757453/ — accessed 18 October 2026.
  5. Rizos EC, Markozannes G, Charitakis N, et al. Continuous glucose monitoring in type 1 diabetes, type 2 diabetes, and diabetes during pregnancy: a systematic review with meta-analysis of randomized controlled trials. Diabetes Technol Ther. 2025;27(7):537-552. doi:10.1089/dia.2024.0599. https://pubmed.ncbi.nlm.nih.gov/40049630/ — accessed 18 October 2026.
  6. Zhu J, Zhang L. Efficacy of continuous glucose monitoring in comparison to self-blood glucose monitoring in patients with type 2 diabetes mellitus under insulin treatment: a systematic review and meta-analysis. BMC Endocr Disord. 2026;26(1):113. doi:10.1186/s12902-026-02167-4. https://pubmed.ncbi.nlm.nih.gov/41942969/ — accessed 18 October 2026.
  7. Wilmot EG, Moore P, Sathyapalan T, et al. Continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes: a randomised, multicentre, open-label, superiority trial. Lancet Diabetes Endocrinol. 2026;14(6):463-474. doi:10.1016/S2213-8587(26)00076-8. https://pubmed.ncbi.nlm.nih.gov/42035781/ — accessed 18 October 2026.

The clinical brief

One question, answered from the evidence

If this was useful, the newsletter arrives weekday mornings: about four minutes, with the source behind each figure.

By subscribing you attest that you are a licensed healthcare professional. We use your email and role only to send the clinical brief. See a sample issue · Privacy · Terms

Get the clinical brief in your inbox

Weekday mornings. One question, answered from the evidence.

  • Figures carry a numbered source
  • One question per issue — about four minutes
  • Unsubscribe from any email, in one click

19 articles · 120 references · 10 therapeutic areas · see a sample issue

By subscribing you attest that you are a licensed healthcare professional. We use your email and role only to send the clinical brief, and you can unsubscribe from any email. Your data is handled per our Privacy Policy and Terms.

We use cookies on this site
We use essential cookies to make the site work, and — only with your consent — analytics cookies to see which clinical topics are read. See our Cookie Policy.
Manage preferences